SCHEMBL21729924

SCHEMBL21729924

NC(=O)[C@@H](N)Cc1ccc(O)c(O)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 6/20 0.74
KDM4E B2RXH2 6/20 0.74
HIF1A Q16665 6/20 0.74
HSD17B10 Q99714 6/20 0.74
SLC7A5 Q01650 5/20 0.74
RECQL P46063 4/20 0.74
TDP1 Q9NUW8 4/20 0.74
PTGS1 P23219 3/20 0.74
USP2 O75604 2/20 0.74
ADORA3 P0DMS8 2/20 0.74
HTR2A P28223 2/20 0.74
PTGS2 P35354 2/20 0.74
EGFR P00533 2/20 0.74
LCK P06239 1/20 0.74
FYN P06241 1/20 0.74
KDM6B O15054 1/20 0.56
PLA2G1B P04054 1/20 0.55
ALOX12 P18054 4/20 0.53
HPGD P15428 4/20 0.53
ALDH1A1 P00352 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1069483 1.00 ALOX15 (0.74) ALOX15KDM4EHIF1AHSD17B10SLC7A5
SCHEMBL13661903 1.00 ALOX15 (0.74) ALOX15KDM4EHIF1AHSD17B10SLC7A5
SCHEMBL20765409 1.00 ALOX15 (0.74) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Hydrochloric Acid SCHEMBL20765475 0.98 ALOX15 (0.72) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Hydrochloric Acid SCHEMBL20764445 0.98 ALOX15 (0.72) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Levodopa SCHEMBL27853956 0.86 SLC7A5 (0.93) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Levodopa SCHEMBL30777603 0.86 SLC7A5 (0.93) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Levodopa SCHEMBL11000382 0.85 SLC7A5 (1.00) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Levodopa SCHEMBL116907 0.85 SLC7A5 (1.00) ALOX15KDM4EHIF1AHSD17B10SLC7A5
Levodopa SCHEMBL704089 0.85 SLC7A5 (1.00) ALOX15KDM4EHIF1AHSD17B10SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3006454-B1 NEW COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING, AND SYNTHESIS, NANO-STRUCTURE AND USE THEREOF SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) 2021-01-13 EP disclosed
US-20200055895-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055895-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SERPINC1, PLAT, F2 ALOX15 332/4885KDM4E 3130/4885HIF1A 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.